Rutherford R M, Azher T, Gilmartin J J
Department of Respiratory Medicine, Merlin Park Hospital, Galway, Ireland.
Ir J Med Sci. 2002 Oct-Dec;171(4):193-6. doi: 10.1007/BF03170278.
Chemotherapy is an established intervention in inoperable non-small cell lung cancer (NSCLC), yet few Irish patients receive this treatment.
To determine survival, toxicity and radiological response following chemotherapy for NSCLC at our institution.
Retrospective audit of all patients receiving chemotherapy for histologically proven, inoperable NSCLC from January 1997 to December 2000.
There were 80 treatment episodes in 77 patients, mean age 62 years. Forty-eight (60%) patients had locally advanced and 32 (40%) metastatic disease. Mitomycin, Ifosfamide, Carboplatin (MIC) and Paclitaxel/Carboplatin (PC) were the most commonly administered regimens. Median survival for locally advanced and metastatic disease was 13.9 months and 7.1 months respectively. Severe neutropenia and thrombocytopenia were each witnessed after less than 9% of cycles. Eleven (16.7%) patients had radiological response including 4 (6.1%) complete responses.
Survival for inoperable NSCLC treated with chemotherapy was encouraging and achieved at low toxicity.
化疗是不可切除非小细胞肺癌（NSCLC）的一种既定治疗方法，但很少有爱尔兰患者接受这种治疗。
确定在我们机构接受化疗的NSCLC患者的生存率、毒性和放射学反应。
对1997年1月至2000年12月期间所有接受化疗的经组织学证实为不可切除NSCLC患者进行回顾性审计。
77例患者共进行了80个疗程的治疗，平均年龄62岁。48例（60%）患者为局部晚期疾病，32例（40%）为转移性疾病。丝裂霉素、异环磷酰胺、卡铂（MIC）和紫杉醇/卡铂（PC）是最常用的治疗方案。局部晚期和转移性疾病的中位生存期分别为13.9个月和7.1个月。不到9%的疗程后出现严重中性粒细胞减少和血小板减少。11例（16.7%）患者有放射学反应，其中4例（6.1%）完全缓解。
化疗治疗不可切除NSCLC的生存率令人鼓舞，且毒性较低。
